[ET Net News Agency, 23 July 2021] Lee's Pharmaceutical Holdings Limited (00950) said
China Oncology Focus Limited (COF), a subsidiary of the company, has enrolled the first
patient in China in the Phase III, multicentre, randomised, double blinded, placebo
control clinical trial of Socazolimab (anti-PD-L1 monoclonal antibody, formerly known as
ZKAB001) combined with chemotherapy in the first-line treatment of extensive-stage
small-cell lung cancer (ESSCLC). The clinical trial approval was granted by China's
National Medical Products Administration (NMPA) on 1 March 2021.
The initiation of this Phase III trial is based on the results from an earlier Phase Ib
trial in which Socazolimab combined with carboplatin and etoposide showed promising
efficacy and safety profile in patients with ES-SCLC. This clinical trial involves 56
centres and is led by Prof. Shun Lu from Shanghai Chest Hospital. (RC)